Insights

MGC Pharmaceuticals (ASX:MXC) share price rockets 40% on supply deal

A new US supply and distribution deal has seen shares in the pharma company soar
The post MGC Pharmaceuticals (ASX:MXC) share price rockets 40% on supply deal appeared first on The Motley Fool Australia. –

The MGC Pharmaceuticals Ltd (ASX: MXC) share price has bolted more than 40% higher in morning trade today.   

Investors are bidding shares in the pharmaceutical company higher after it released an announcement earlier today. At the time of writing, MGC shares are swapping hands for 5.5 cents, up 41%.

Let’s take a look at what MGC Pharmaceuticals announced.

MGC Pharma share price bolts on US supply agreement

Earlier today, MGC Pharma informed shareholders the company has entered a binding, 3-year US supply and distribution agreement.

The agreement with US-based company, AMC Holdings Inc (AMC), includes a minimum supply order of US$24million.

A range of MGC’s phytomedicine products is included in the agreement, namely; CannEpil, CogniCann, and CimetrA.

Under the agreement, AMC will act as a licenced distributor and undertake all marketing activities in the US. In addition, the company will also manage the importing and warehousing of MGC Pharma’s products.

In addition to supply, AMC will also be responsible for coordinating relevant clinical trial processes for MGC Pharma’s products.  

The agreement also outlines a minimum US$3 million of sales in Year 1.

Additionally, MGC Pharma can terminate the agreement if AMC fails to secure regulatory approval for at least 1 of the listed MGC products by 30 September 2021.

What did management say?

MGC Pharmaceuticals’ management highlighted the importance of the company’s milestone of expanding into the US. 

Co-founder and managing director Roby Zomer commented:

This is an important milestone agreement for MGC Pharma, as it provides MGC access to the largest healthcare market in the world. We look forward to working with our new partners at AMC and utilising their expertise and network to widen patient access to MGC’s phytomedicine products.

Snapshot of the MGC Pharmaceuticals share price

The MGC Pharma share price has had an extremely volatile year thus far. Shares in the company bolted to record highs earlier in the year after listing on the London Stock Exchange (LSE).

Since then, the MGC Pharmaceuticals share price has whittled away from its highs throughout the year.

At the time of writing, MGC shares are trading 41% higher for the day. The MGC Pharmaceuticals share price was up more than 50% earlier today, after hitting an intra-day high of 6 cents per share.

Including today’s bullish price action, shares in MGC are trading around 118% higher year to date.

The post MGC Pharmaceuticals (ASX:MXC) share price rockets 40% on supply deal appeared first on The Motley Fool Australia.

Should you invest $1,000 in MGC Pharmaceuticals right now?

Before you consider MGC Pharmaceuticals, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and MGC Pharmaceuticals wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why the Mineral Resources (ASX:MIN) share price has beaten the ASX 200 in the last year
What has happened to the Baby Bunting (ASX:BBN) share price this year?
ASX 200 midday update: Wesfarmers’ $2.3bn capital return, Appen & Pilbara Minerals fall

Secos (ASX:SES) share price soars 6% on FY21 earnings 
Leading brokers give their verdict on the A2 Milk (ASX:A2M) share price

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!